Related Experiment Video
Updated: Jan 23, 2026
Author Spotlight: Modeling Brain Tumors In Vivo Using Electroporation-Based Delivery of Plasmid DNA Representing Patient Mutation Signatures
Published on: June 23, 2023
Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas
Shuyu Hao1, Guanyou Huang2,3, Jie Feng4
1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, 119 Nan Si Huan Xi Road, Feng Tai District, Beijing, 100070, China. shuyuhao@hotmail.com.
Aims:
Skull base meningiomas represent approximately 25% of all meningiomas, nearly 20% of which are atypical or anaplastic. To date, effective medical treatments for meningiomas are still lacking. Genetic aberrations (TRAF7, KLF4, AKT1, and SMO) and the effects of genetic aberrations on the expression of inhibitory immune checkpoint molecules (PD-L1, IDO, and TDO2) in skull base meningiomas are still unclear.
Methods:
Genetic alterations in the four genes were identified in 92 skull base meningiomas by Sanger sequencing. The expression differences in immune checkpoints between mutant and wild-type (WT) tumors were determined by immunohistochemistry (IHC) and Western blot (WB).
Results:
The four mutations were not concurrently detected in the patients with skull base meningiomas. Among the tumors from the KLF4-mutated group, almost half were petroclival meningiomas. KLF4- and TRAF7-mutated tumors were predominantly secretory meningiomas. SMO-mutated tumors exhibited higher calcification, and half of these tumors were observed in the brain midline. Receiver operating characteristic curve analysis indicated that tumor volume can predict KLF4 and TRAF7 mutation status with high sensitivity and specificity, respectively. The IHC and WB analyses indicated that PD-L1, IDO, and TDO2 levels in tumors with TRAF7 mutations were significantly higher than those in WT tumors. Meanwhile, there was a significant difference in TDO2 between tumors with AKT1 mutations and WT tumors. Specifically, TRAF7 mutations could play a key role in skull base meningiomas by regulating the expression of inhibitory immune checkpoints and thus suppressing immune responses.
Conclusions:
Checkpoint inhibitors may be potential strategies for targeted immunotherapies of these mutant meningiomas.
Insights
Genetic mutations in skull base meningiomas, particularly TRAF7, influence immune checkpoint molecule expression. This suggests targeted immunotherapies using checkpoint inhibitors may offer new treatment strategies for these challenging tumors.
Area of Science:
- Neuro-oncology
- Molecular genetics
- Immunology
Background:
- Skull base meningiomas constitute a significant portion of meningiomas, with limited effective medical treatments available.
- Understanding the genetic landscape and its impact on immune evasion is crucial for developing novel therapies.
- Specific genetic aberrations (TRAF7, KLF4, AKT1, SMO) and their link to immune checkpoints (PD-L1, IDO, TDO2) in these tumors remain largely unexplored.
Purpose of the Study:
- To investigate the prevalence of genetic aberrations in TRAF7, KLF4, AKT1, and SMO genes in skull base meningiomas.
- To determine the correlation between these genetic mutations and the expression levels of immune checkpoint molecules.
- To explore the potential therapeutic implications of these findings for skull base meningiomas.
Main Methods:
- Sanger sequencing was employed to identify genetic alterations in 92 skull base meningioma samples.
- Immunohistochemistry (IHC) and Western blot (WB) analyses were used to assess immune checkpoint expression.
- Correlation analysis was performed between specific gene mutations and clinical/pathological features.
Main Results:
- No concurrent mutations were found among the four studied genes.
- KLF4 mutations were associated with petroclival meningiomas, while KLF4 and TRAF7 mutations were linked to secretory meningiomas.
- SMO mutations correlated with increased calcification and midline location.
- TRAF7 mutations significantly upregulated PD-L1, IDO, and TDO2 expression, suggesting immune suppression.
- AKT1 mutations showed a significant difference in TDO2 expression compared to wild-type tumors.
Conclusions:
- TRAF7 mutations play a critical role in skull base meningiomas by modulating immune checkpoint expression and suppressing anti-tumor immunity.
- Checkpoint inhibitors represent a promising avenue for targeted immunotherapy in mutant meningiomas.
- Further research into these genetic-immune interactions could lead to personalized treatment strategies.
More Related Videos
Related Concept Videos
01:39Mutations
01:35Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
02:19The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
00:36Viral Mutations
02:35Key Elements for Plant Nutrition
01:22Sutures of the Skull
Sutures are immobile joints between adjacent bones of the skull. The narrow gap between the bones is filled with dense, fibrous connective tissue that unites the bones. The long sutures located between the skull bones are not straight but instead follow irregular, tightly twisting paths. These twisting lines tightly...